Unum Group stock may be fully priced despite its $3.8 billion long term care reinsurance deal, as valuation signals pull in different directions. The Excess Returns intrinsic value estimate points to a 48.4% discount to current pricing, while the earnings multiple read leans expensive. The long term care reinsurance deals can support the case for a cleaner balance sheet and a more focused employee benefits franchise, but the remaining legacy long term care exposure still matters for how investors price risk. On Simply Wall St's broader checks, Unum Group only clears two of six valuation tests, suggesting the stock does not screen as a clear bargain overall.
Unum GroupArticle discusses valuation signals pulling in different directions and a $3.8B LTC reinsurance deal, but overall assessment is mixed with no clear positive or negative catalyst.